CA2436209A1 - Formulation pharmaceutique contenant des pyrazolo[4,3-d]pyrimidines et des nitrates ou des thienopyrimidines et des nitrates - Google Patents
Formulation pharmaceutique contenant des pyrazolo[4,3-d]pyrimidines et des nitrates ou des thienopyrimidines et des nitrates Download PDFInfo
- Publication number
- CA2436209A1 CA2436209A1 CA002436209A CA2436209A CA2436209A1 CA 2436209 A1 CA2436209 A1 CA 2436209A1 CA 002436209 A CA002436209 A CA 002436209A CA 2436209 A CA2436209 A CA 2436209A CA 2436209 A1 CA2436209 A1 CA 2436209A1
- Authority
- CA
- Canada
- Prior art keywords
- pyrimidin
- chloro
- acid
- methyl
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne une préparation pharmaceutique contenant au moins un inhibiteur de la phosphodiestérase V et au moins un nitrate et destinée à la production d'un médicament pour le traitement d'une angine, hypertension artérielle, hypertension pulmonaire, insuffisance cardiaque congestive, bronchopneumopathie chronique obstructive, coeur pulmonaire, insuffisance cardiaque droite, athérosclérose, passage réduit dans les vaisseaux cardiaques, maladies vasculaires périphériques, attaque d'apoplexie, bronchite, asthme allergique, asthme chronique coryza allergique, glaucome, côlon irritable, tumeurs, d'insuffisance rénale et de cirrhose du foie.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10104096.2 | 2001-01-31 | ||
DE2001104097 DE10104097A1 (de) | 2001-01-31 | 2001-01-31 | Pharmazeutische Formulierung enthaltend Thienopyrimidine und Nitrate |
DE2001104096 DE10104096A1 (de) | 2001-01-31 | 2001-01-31 | Pharmazeutische Formulierung enthaltend Thienopyrimidine und Nitrate |
DE10104097.0 | 2001-01-31 | ||
DE10104095.4 | 2001-01-31 | ||
DE2001104095 DE10104095A1 (de) | 2001-01-31 | 2001-01-31 | Pharmazeutische Formulierung enthaltend Pyrazolo [4,3-d]pyrimidine und Nitrate |
PCT/EP2001/015324 WO2002060449A2 (fr) | 2001-01-31 | 2001-12-27 | Formulation pharmaceutique contenant des pyrazolo[4,3-d]pyrimidines et des nitrates ou des thienopyrimidines et des nitrates |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2436209A1 true CA2436209A1 (fr) | 2002-08-08 |
Family
ID=27214255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002436209A Abandoned CA2436209A1 (fr) | 2001-01-31 | 2001-12-27 | Formulation pharmaceutique contenant des pyrazolo[4,3-d]pyrimidines et des nitrates ou des thienopyrimidines et des nitrates |
Country Status (14)
Country | Link |
---|---|
US (1) | US20040077664A1 (fr) |
EP (1) | EP1355649A2 (fr) |
JP (1) | JP2004517940A (fr) |
KR (1) | KR20030070149A (fr) |
CN (1) | CN1499969A (fr) |
AR (1) | AR035741A1 (fr) |
BR (1) | BR0116849A (fr) |
CA (1) | CA2436209A1 (fr) |
CZ (1) | CZ20032339A3 (fr) |
HU (1) | HUP0302987A2 (fr) |
MX (1) | MXPA03006717A (fr) |
PL (1) | PL362408A1 (fr) |
SK (1) | SK10762003A3 (fr) |
WO (1) | WO2002060449A2 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10325813B4 (de) | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxe und/oder Therapie bei der portalen Hypertonie |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
WO2005097799A1 (fr) * | 2004-04-07 | 2005-10-20 | Pfizer Limited | Pyrazolo`4,3[4,3-d]pyrimidines |
JPWO2006126718A1 (ja) * | 2005-05-27 | 2008-12-25 | 田辺三菱製薬株式会社 | ピラゾロピリミジン誘導体 |
EP1941876A1 (fr) * | 2006-12-28 | 2008-07-09 | Lacer, S.A. | Derivés du mononitrite de l'isosorbide destinées au traitement de l'inflammation et l'hypertension oculaire |
CN103119047B (zh) | 2010-07-23 | 2016-06-15 | 哈佛大学校长及研究员协会 | 三环类蛋白酶体活性增强化合物 |
US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2013112706A1 (fr) | 2012-01-25 | 2013-08-01 | Proteostasis Therapeutics, Inc. | Composés permettant de moduler l'activité de protéasome |
SE542968C2 (en) | 2018-10-26 | 2020-09-22 | Lindahl Anders | Treatment of osteoarthritis |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5294612A (en) * | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
US5656629A (en) * | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
DE19644228A1 (de) * | 1996-10-24 | 1998-04-30 | Merck Patent Gmbh | Thienopyrimidine |
US6043252A (en) * | 1997-05-05 | 2000-03-28 | Icos Corporation | Carboline derivatives |
DE19752952A1 (de) * | 1997-11-28 | 1999-06-02 | Merck Patent Gmbh | Thienopyrimidine |
DE19819023A1 (de) * | 1998-04-29 | 1999-11-04 | Merck Patent Gmbh | Thienopyrimidine |
-
2001
- 2001-12-27 MX MXPA03006717A patent/MXPA03006717A/es unknown
- 2001-12-27 KR KR10-2003-7010043A patent/KR20030070149A/ko not_active Application Discontinuation
- 2001-12-27 EP EP01988079A patent/EP1355649A2/fr not_active Withdrawn
- 2001-12-27 SK SK1076-2003A patent/SK10762003A3/sk unknown
- 2001-12-27 BR BR0116849-5A patent/BR0116849A/pt not_active Application Discontinuation
- 2001-12-27 HU HU0302987A patent/HUP0302987A2/hu unknown
- 2001-12-27 PL PL01362408A patent/PL362408A1/xx unknown
- 2001-12-27 US US10/470,485 patent/US20040077664A1/en not_active Abandoned
- 2001-12-27 JP JP2002560641A patent/JP2004517940A/ja active Pending
- 2001-12-27 WO PCT/EP2001/015324 patent/WO2002060449A2/fr not_active Application Discontinuation
- 2001-12-27 CN CNA018224385A patent/CN1499969A/zh active Pending
- 2001-12-27 CZ CZ20032339A patent/CZ20032339A3/cs unknown
- 2001-12-27 CA CA002436209A patent/CA2436209A1/fr not_active Abandoned
-
2002
- 2002-01-30 AR ARP020100323A patent/AR035741A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
SK10762003A3 (sk) | 2004-01-08 |
PL362408A1 (en) | 2004-11-02 |
JP2004517940A (ja) | 2004-06-17 |
EP1355649A2 (fr) | 2003-10-29 |
AR035741A1 (es) | 2004-07-07 |
US20040077664A1 (en) | 2004-04-22 |
MXPA03006717A (es) | 2003-10-24 |
CZ20032339A3 (cs) | 2004-09-15 |
KR20030070149A (ko) | 2003-08-27 |
WO2002060449A2 (fr) | 2002-08-08 |
CN1499969A (zh) | 2004-05-26 |
WO2002060449A3 (fr) | 2003-01-30 |
BR0116849A (pt) | 2004-02-25 |
HUP0302987A2 (hu) | 2003-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2311922C (fr) | Thienopyrimidines | |
US20040034040A1 (en) | Use of thienopyrimidines | |
CA2384037C (fr) | Pyrazolo[4,3-d]pyrimidines | |
US6787548B1 (en) | Thienopyrimidines as phosphodiesterase inhibitors | |
US20040063731A1 (en) | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | |
CA2436209A1 (fr) | Formulation pharmaceutique contenant des pyrazolo[4,3-d]pyrimidines et des nitrates ou des thienopyrimidines et des nitrates | |
US20040023990A1 (en) | Use of pyrazolo[4,3-d]pyrimidines | |
US20040023991A1 (en) | Use of pyrazolo[4,3-d]pyrimidines | |
AU2001237379B2 (en) | Use of benzothieno-2,3-D-pyrimidines with PDE V inhibitory effect for the treatment of erectile dysfunction | |
US6780867B2 (en) | Thienopyrimidines | |
CA2387123A1 (fr) | Utilisation de thienopyrimidines | |
ZA200306730B (en) | Pharmaceutical formulation containing pyrazolo[4,3-d] pyrimidine and nitrates or thienopyrimidines and nitrates. | |
AU2002235832A1 (en) | Pharmaceutical formulation comprising pyrazolo[4,3-d] pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |